|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
DK2826860T3
(en)
|
2010-04-23 |
2018-12-03 |
Univ Massachusetts |
CNS targeting AAV vectors and methods for their use
|
|
ES2704677T3
(es)
|
2013-04-18 |
2019-03-19 |
Fond Telethon |
Suministro eficaz de genes grandes por vectores de AAV duales
|
|
CA2907799A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
WO2015168666A2
(en)
*
|
2014-05-02 |
2015-11-05 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP3795580A1
(en)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
RU2020108189A
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
MX2017006217A
(es)
|
2014-11-14 |
2018-05-02 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
|
US20180057839A1
(en)
*
|
2014-11-26 |
2018-03-01 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
JP7064214B2
(ja)
*
|
2015-09-28 |
2022-05-10 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
抗体回避性ウイルスベクターのための方法および組成物
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US12188037B2
(en)
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
GB201519086D0
(en)
*
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
RU2021102893A
(ru)
|
2015-11-05 |
2021-03-03 |
Бамбу Терапьютикс, Инк. |
Модифицированные гены атаксии фридрейха и векторы для генной терапии
|
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
DK3387137T3
(da)
*
|
2015-12-11 |
2021-05-03 |
California Inst Of Techn |
Målretningspeptider til styring af adeno-associerede virusser (aav`er)
|
|
WO2017106354A1
(en)
*
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
EP3413928B1
(en)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
IL322403A
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Preparations for the treatment of wet age-related macular degeneration
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics, Inc. |
composições e métodos de tratamento da doença de huntington
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
MA44546B1
(fr)
*
|
2016-06-15 |
2021-03-31 |
Univ California |
Virus adéno-associés variants et procédés d'utilisation
|
|
RU2753194C2
(ru)
|
2016-06-21 |
2021-08-12 |
Бамбу Терапьютикс, Инк. |
Оптимизированные гены и экспрессионные кассеты мини-дистрофина и их применение
|
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
WO2018011572A1
(en)
|
2016-07-12 |
2018-01-18 |
The University Of Manchester |
Gene therapy
|
|
CA3029833A1
(en)
|
2016-07-29 |
2018-02-01 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
JP7226801B2
(ja)
*
|
2016-08-16 |
2023-02-21 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
標的遺伝子導入のための方法および組成物
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
AU2017345470B2
(en)
*
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
IL266264B2
(en)
|
2016-11-04 |
2023-11-01 |
Baxalta Inc |
Adeno-associated virus formulations
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
JP7237843B2
(ja)
|
2017-02-21 |
2023-03-13 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
修飾されたａａｖキャプシドタンパク質およびその使用
|
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US11920148B2
(en)
|
2017-02-22 |
2024-03-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
WO2018191666A1
(en)
|
2017-04-14 |
2018-10-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
CA3061652A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CN110831611A
(zh)
*
|
2017-05-10 |
2020-02-21 |
马萨诸塞眼科耳科诊所 |
用于修饰病毒的组装活化蛋白(aap)依赖性的方法和组合物
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
BR112019019015A2
(pt)
|
2017-06-30 |
2020-04-14 |
Univ California |
vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
|
WO2019040586A1
(en)
*
|
2017-08-25 |
2019-02-28 |
Ovid Therapeutics Inc. |
RECOMBINANT ADENO-ASSOCIATE VECTORS
|
|
EP3676373A4
(en)
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Ｓｏｄ１二重発現ベクターおよびその使用
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
CN111727201A
(zh)
*
|
2017-10-18 |
2020-09-29 |
再生生物股份有限公司 |
完全人源翻译后修饰的抗体治疗剂
|
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
WO2019178412A1
(en)
*
|
2018-03-16 |
2019-09-19 |
Research Institute At Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
|
CN112218880A
(zh)
*
|
2018-03-29 |
2021-01-12 |
阿斯克肋匹奥生物制药公司 |
逃避中和的肝趋向性重组aav6载体
|
|
US12091435B2
(en)
|
2018-04-03 |
2024-09-17 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
MX2020010464A
(es)
|
2018-04-03 |
2021-01-29 |
|
Vectores de virus que evitan anticuerpos.
|
|
CN108660159B
(zh)
*
|
2018-04-12 |
2020-10-30 |
四川大学 |
重组蝙蝠腺相关病毒载体及其用途
|
|
KR102051393B1
(ko)
|
2018-05-04 |
2019-12-04 |
(주)지뉴인텍 |
아데노부속바이러스 기반 유전자 전달용 재조합 벡터 및 이를 이용한 암질환 예방 또는 치료용 조성물
|
|
AU2019270900B2
(en)
|
2018-05-15 |
2026-03-12 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
AU2019268330A1
(en)
|
2018-05-15 |
2020-11-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2020014479A1
(en)
|
2018-07-11 |
2020-01-16 |
Baxalta Incorporated |
Aav compositions
|
|
EA202190358A1
(ru)
*
|
2018-07-31 |
2021-05-04 |
Корнелл Юниверсити |
Способы генной терапии для контроля функции органов
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CN119684417A
(zh)
|
2018-10-02 |
2025-03-25 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020102645A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|
|
GB201900702D0
(en)
|
2019-01-18 |
2019-03-06 |
Univ Bristol |
Therapy
|
|
EP3911410A1
(en)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
CN113728108A
(zh)
*
|
2019-02-15 |
2021-11-30 |
桑格摩生物治疗股份有限公司 |
用于生产重组aav的组合物和方法
|
|
JP7698583B2
(ja)
|
2019-03-21 |
2025-06-25 |
ギンコ バイオワークス インコーポレイテッド |
組換えアデノ随伴ウイルスベクター
|
|
KR20210142725A
(ko)
*
|
2019-03-28 |
2021-11-25 |
오피노 엘엘씨 |
코어 페이징 처리
|
|
SG11202110607WA
(en)
|
2019-04-01 |
2021-10-28 |
Tenaya Therapeutics Inc |
Adeno-associated virus with engineered capsid
|
|
CA3136872A1
(en)
*
|
2019-04-23 |
2020-10-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New adeno-associated virus (aav) variants and uses thereof for gene therapy
|
|
AU2020263757B2
(en)
|
2019-04-24 |
2025-08-28 |
Takara Bio Inc. |
AAV mutant having brain-targeting property
|
|
CN113767110A
(zh)
*
|
2019-04-26 |
2021-12-07 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
US12173290B2
(en)
|
2019-06-28 |
2024-12-24 |
Crispr Therapeutics Ag |
Materials and methods for controlling gene editing
|
|
US20220372512A1
(en)
*
|
2019-07-04 |
2022-11-24 |
Children's Medical Research Institute |
Methods and aav vectors for in vivo transduction
|
|
WO2021009805A1
(ja)
*
|
2019-07-12 |
2021-01-21 |
株式会社遺伝子治療研究所 |
ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
EP3999119B1
(en)
*
|
2019-07-15 |
2024-09-11 |
Meiragtx UK II Limited |
Modified aav capsid proteins for treatment of arthritic disease
|
|
WO2021030764A1
(en)
*
|
2019-08-14 |
2021-02-18 |
University Of Florida Research Foundation, Incorporated |
Aav capsid variants for gene therapy
|
|
JP2022545534A
(ja)
*
|
2019-08-29 |
2022-10-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ヒト血液脳関門を通過するためのアデノ随伴ウイルスベクター
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4041755A4
(en)
*
|
2019-10-10 |
2023-10-25 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
EP4045664A1
(en)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
|
IL292297A
(en)
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
BR112022014852A2
(pt)
*
|
2020-01-29 |
2022-10-11 |
Genzyme Corp |
Proteínas modificadas do capsídeo viral adenoassociado para terapia gênica ocular e métodos de uso das mesmas
|
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
IL298001A
(en)
|
2020-05-13 |
2023-01-01 |
Voyager Therapeutics Inc |
Redirecting tropism of adeno-associated virus capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010009D0
(en)
*
|
2020-06-30 |
2020-08-12 |
Syncona Investment Man Ltd |
Vector
|
|
WO2022026409A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
CN111825772B
(zh)
*
|
2020-07-30 |
2023-10-20 |
中国科学院精密测量科学与技术创新研究院 |
具有变异衣壳蛋白的腺相关病毒及其应用
|
|
CA3181024A1
(en)
|
2020-08-06 |
2022-02-10 |
Fundacion Para La Investigacion Medica Aplicada |
Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
|
|
BR112023002374A2
(pt)
|
2020-08-12 |
2023-03-21 |
UCB Biopharma SRL |
Terapia genética usando construções de ácido nucléico compreendendo sequências promotoras de proteína 2 de ligação de metil cpg (mecp2)
|
|
CA3189878A1
(en)
|
2020-08-19 |
2022-02-24 |
Colin O'BANION |
Adeno-associated virus vectors for treatment of rett syndrome
|
|
JP7811576B2
(ja)
*
|
2020-08-28 |
2026-02-05 |
ジョイント・ストック・カンパニー “バイオキャド” |
ＳＡＲＳ－ＣｏＶ－２に対するＡＡＶ５に基づくワクチン
|
|
CN113754728B
(zh)
*
|
2020-09-30 |
2022-07-12 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
MX2023003699A
(es)
*
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
CN115698304A
(zh)
|
2020-10-09 |
2023-02-03 |
特纳亚治疗股份有限公司 |
亲斑蛋白-2基因疗法的方法和组合物
|
|
CN116390935A
(zh)
|
2020-10-09 |
2023-07-04 |
Ucb生物制药有限责任公司 |
核酸构建体、病毒载体和病毒颗粒
|
|
CN116490514A
(zh)
|
2020-10-28 |
2023-07-25 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
|
WO2022093769A1
(en)
*
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
EP4240861A1
(en)
|
2020-11-03 |
2023-09-13 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
AU2021378075B2
(en)
|
2020-11-11 |
2025-03-27 |
Borea Therapeutics S.R.L. |
Modified viral particles for gene therapy
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
US20240011048A1
(en)
|
2020-12-21 |
2024-01-11 |
Pfizer Inc. |
Methods and compositions for inhibiting excess nucleic acid precipitation
|
|
AU2021404944A1
(en)
|
2020-12-23 |
2023-07-06 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
|
CN112961219B
(zh)
*
|
2021-02-24 |
2022-08-12 |
中国农业科学院生物技术研究所 |
重组腺相关病毒、其突变体及其构建方法和应用
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
CN117355342A
(zh)
*
|
2021-05-07 |
2024-01-05 |
奥伊斯特普安生物制药公司 |
编码神经营养因子的腺相关病毒病毒颗粒和其用途
|
|
KR20240005950A
(ko)
|
2021-05-12 |
2024-01-12 |
폰다지오네 텔레톤 이티에스 |
벡터 시스템
|
|
EP4359547A1
(en)
|
2021-06-22 |
2024-05-01 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
|
MX2024005171A
(es)
|
2021-10-28 |
2024-05-13 |
UCB Biopharma SRL |
Constructos de acido nucleico, vectores viricos y particulas viricas.
|
|
WO2023081648A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
EP4426331A1
(en)
|
2021-11-02 |
2024-09-11 |
University of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
EP4442830A4
(en)
|
2021-11-29 |
2025-04-30 |
Shanghai Regenelead Therapies Co., Ltd. |
AADC/GDNF polynucleotide and use thereof in the treatment of Parkinson's disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
AU2022423978A1
(en)
*
|
2021-12-28 |
2024-07-18 |
Chengdu Origen Biotechnology Co., Ltd. |
Modified aav capsid protein and use thereof
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
JP2025507751A
(ja)
|
2022-03-01 |
2025-03-21 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物
|
|
CA3255225A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
AR129843A1
(es)
*
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
US20260041792A1
(en)
*
|
2022-07-12 |
2026-02-12 |
University Of Florida Research Foundation, Incorporated |
Novel aav3b capsid variants with enhanced hepatocyte tropism
|
|
KR20240014846A
(ko)
*
|
2022-07-26 |
2024-02-02 |
숙명여자대학교산학협력단 |
Aav2-anks1a 재조합 바이러스를 포함하는 알츠하이머 질병 치료용 조성물
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
CN116063404B
(zh)
*
|
2022-09-27 |
2025-08-29 |
广州译码基因科技有限公司 |
可提高AAV包装能力的衣壳蛋白MutD及其应用
|
|
GB202216168D0
(en)
|
2022-10-31 |
2022-12-14 |
UCB Biopharma SRL |
Route of administration
|
|
CN116041443B
(zh)
*
|
2022-12-30 |
2023-09-22 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
CN115925819B
(zh)
*
|
2022-12-30 |
2023-10-13 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
EP4646485A1
(en)
*
|
2023-01-05 |
2025-11-12 |
Emugen Therapeutics LLC |
Chimeric aav and uses thereof
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
WO2024189094A1
(en)
|
2023-03-14 |
2024-09-19 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202304767D0
(en)
*
|
2023-03-30 |
2023-05-17 |
Ucl Business Ltd |
Synthetic AAV Capsid
|
|
WO2024238853A1
(en)
*
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2025022290A1
(en)
|
2023-07-21 |
2025-01-30 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025049917A1
(en)
*
|
2023-08-31 |
2025-03-06 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
CN118440161B
(zh)
*
|
2024-01-16 |
2025-02-25 |
沈阳兴齐眼药股份有限公司 |
提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025228976A1
(en)
|
2024-04-29 |
2025-11-06 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025262203A1
(en)
|
2024-06-21 |
2025-12-26 |
UCB Biopharma SRL |
Nucleic acid sequences
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|